Recursion Pharmaceuticals enters today's earnings with a short position that dwarfs most of its closest peers. Short interest runs at 31.5% of free float, roughly 162 million shares, while correlated names like CRSP and SANA carry far lighter positioning. Among the peer group, ABSI and PRME both surged more than 20% last week…
RXRX short interest squeeze risk escalates: utilization hits 91.39%, highest level in 52 weeks, while 35.4% of free float remains shorted.
Key data as of 12 Nov 2026
Three signals converged on RXRX Tuesday. Availability has hit zero. Short interest sits at a multi-month high. And options traders are piling into calls, not puts. The signals point in different directions — and that…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RXRX — free to start on ORTEX.
Sign up for free →Open RXRX on ORTEX